A randomized, placebo-controlled trial reported evidence supporting antenatal N-acetylcysteine (NAC) supplementation for pregnant women facing imminent preterm birth. The study, by Küster et al., was published in Pediatric Research and evaluated NAC as a preventive intervention. The trial design focused on a high-risk cohort with imminent delivery risk, targeting outcomes that typically include gestational age and neonatal morbidity. The brief characterizes the results as compelling enough to suggest the approach could reshape prenatal management for at-risk pregnancies. The translational significance is that NAC is a widely known redox-active molecule, potentially lowering barriers to clinical adoption if efficacy and safety signals are sustained across larger or confirmatory studies. For biotech and neonatology programs, the immediate question is whether NAC can be positioned alongside standard obstetric risk mitigation strategies and whether biomarkers or subgroup analyses identify who benefits most.